The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a regulatory blow to one of its key products in the European market, the European Medicines Agency's CHMP has recommended revoking the EU marketing authorization for TAVNEOS (avacopan), according to reports. The drug, used to treat ANCA-associated vasculitis, is marketed by Vifor Fresenius Medical Care Renal Pharma in partnership with CSL.
The recommendation follows an Article 20 non-pharmacovigilance procedure, though specific reasons remain undisclosed. TAVNEOS is a significant part of CSL's rare-disease portfolio, and its potential withdrawal could impact the company's revenue stream in the region. Markets are now awaiting the European Commission's final decision, which typically follows CHMP recommendations.
Sign in to access this content
Sign InCSL shares closed at A$388.40 on June 25, 2026, after trading between A$384.20 and A$397.16 during the session. Investors are now focused on the European Commission's final ruling, expected in the coming weeks, and any updates on CSL's contingency plans should TAVNEOS lose its EU marketing authorization.